Atossa Therapeutics (NASDAQ:ATOS) Given New $6.00 Price Target at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) had its target price upped by equities researchers at HC Wainwright from $4.00 to $6.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 304.04% from the stock’s previous close.

Separately, cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th.

Read Our Latest Stock Analysis on ATOS

Atossa Therapeutics Stock Down 0.3 %

Shares of Atossa Therapeutics stock traded down $0.01 during mid-day trading on Monday, reaching $1.49. 1,143,231 shares of the stock traded hands, compared to its average volume of 1,396,931. Atossa Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.31. The business has a 50-day moving average of $1.56 and a 200 day moving average of $1.08. The stock has a market capitalization of $186.07 million, a PE ratio of -6.29 and a beta of 1.27.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.06) earnings per share for the quarter. On average, equities research analysts expect that Atossa Therapeutics will post -0.28 EPS for the current fiscal year.

Insider Activity

In related news, Director Jonathan Finn purchased 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was acquired at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the purchase, the director now owns 25,000 shares in the company, valued at $44,250. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 7.80% of the company’s stock.

Institutional Trading of Atossa Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares in the last quarter. PFG Investments LLC bought a new position in Atossa Therapeutics during the first quarter worth about $43,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Atossa Therapeutics during the 3rd quarter valued at about $98,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Read More

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with's FREE daily email newsletter.